CD19 and diffuse large B-cell lymphoma: For relapsed or refractory DLBCL patients, salvage treatment strategies include either CD20 or CD79b-directed antibodies or antibody-drug conjugates, CD19-directed antibodies, and CAR-T cells as well as bone marrow or peripheral blood stem cell transplantation [51,52,53,54,55,56,57].